Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.01
BAX's Cash-to-Debt is ranked lower than
55% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.24 vs. BAX: 1.01 )
Ranked among companies with meaningful Cash-to-Debt only.
BAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 0.31 Max: 1.13
Current: 1.01
0.17
1.13
Equity-to-Asset 0.53
BAX's Equity-to-Asset is ranked lower than
58% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. BAX: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
BAX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.24  Med: 0.34 Max: 0.53
Current: 0.53
0.24
0.53
Interest Coverage 8.13
BAX's Interest Coverage is ranked lower than
75% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.78 vs. BAX: 8.13 )
Ranked among companies with meaningful Interest Coverage only.
BAX' s Interest Coverage Range Over the Past 10 Years
Min: 3.08  Med: 17.4 Max: 32.02
Current: 8.13
3.08
32.02
Piotroski F-Score: 5
Altman Z-Score: 5.44
Beneish M-Score: -2.62
WACC vs ROIC
6.75%
7.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 7.12
BAX's Operating Margin % is ranked higher than
57% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.97 vs. BAX: 7.12 )
Ranked among companies with meaningful Operating Margin % only.
BAX' s Operating Margin % Range Over the Past 10 Years
Min: 4.5  Med: 17.94 Max: 22.9
Current: 7.12
4.5
22.9
Net Margin % 48.85
BAX's Net Margin % is ranked higher than
99% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.14 vs. BAX: 48.85 )
Ranked among companies with meaningful Net Margin % only.
BAX' s Net Margin % Range Over the Past 10 Years
Min: 9.71  Med: 16.5 Max: 48.85
Current: 48.85
9.71
48.85
ROE % 57.28
BAX's ROE % is ranked higher than
98% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.92 vs. BAX: 57.28 )
Ranked among companies with meaningful ROE % only.
BAX' s ROE % Range Over the Past 10 Years
Min: 11.41  Med: 30.38 Max: 57.95
Current: 57.28
11.41
57.95
ROA % 28.99
BAX's ROA % is ranked higher than
98% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.97 vs. BAX: 28.99 )
Ranked among companies with meaningful ROA % only.
BAX' s ROA % Range Over the Past 10 Years
Min: 4.11  Med: 11.59 Max: 28.99
Current: 28.99
4.11
28.99
ROC (Joel Greenblatt) % 86.91
BAX's ROC (Joel Greenblatt) % is ranked higher than
94% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.87 vs. BAX: 86.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 5.65  Med: 39.84 Max: 91.88
Current: 86.91
5.65
91.88
3-Year Revenue Growth Rate 2.50
BAX's 3-Year Revenue Growth Rate is ranked lower than
55% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. BAX: 2.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.2  Med: 6.7 Max: 17.3
Current: 2.5
-10.2
17.3
3-Year EBITDA Growth Rate 71.00
BAX's 3-Year EBITDA Growth Rate is ranked higher than
97% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. BAX: 71.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BAX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -28.3  Med: 7 Max: 71
Current: 71
-28.3
71
3-Year EPS without NRI Growth Rate 151.00
BAX's 3-Year EPS without NRI Growth Rate is ranked higher than
98% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. BAX: 151.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BAX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44  Med: 7.1 Max: 151
Current: 151
-44
151
» BAX's 10-Y Financials

Financials (Next Earnings Date: 2017-04-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BAX Guru Trades in Q1 2016

Joel Greenblatt 1,695,068 sh (New)
David Einhorn 1,198,663 sh (+138.07%)
Keeley Asset Management Corp 61,500 sh (+21.66%)
Vanguard Health Care Fund 11,176,980 sh (+16.94%)
Jim Simons 517,032 sh (+5.06%)
Murray Stahl 14,122 sh (+0.71%)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Tom Gayner 22,000 sh (unchged)
Daniel Loeb 53,850,000 sh (unchged)
John Rogers Sold Out
Jeff Auxier Sold Out
Jana Partners Sold Out
Louis Moore Bacon Sold Out
Lee Ainslie Sold Out
Tweedy Browne 2,492,683 sh (-0.12%)
Charles Brandes 310,615 sh (-1.51%)
Mario Gabelli 153,750 sh (-2.01%)
John Buckingham 81,062 sh (-5.58%)
Manning & Napier Advisors, Inc 149,096 sh (-6.94%)
George Soros 448,200 sh (-9.45%)
Mairs and Power 2,035,912 sh (-9.63%)
Richard Pzena 4,084,406 sh (-13.78%)
Paul Tudor Jones 64,681 sh (-19.04%)
Jeremy Grantham 32,592 sh (-37.62%)
Steven Cohen 51,000 sh (-94.26%)
First Eagle Investment 1,100 sh (-99.86%)
» More
Q2 2016

BAX Guru Trades in Q2 2016

John Hussman 175,000 sh (New)
Leucadia National 700,000 sh (New)
Lee Ainslie 73,700 sh (New)
First Eagle Investment 2,129,733 sh (+193512.09%)
Jim Simons 583,200 sh (+12.80%)
Jeremy Grantham 36,465 sh (+11.88%)
Tom Gayner 22,000 sh (unchged)
Murray Stahl 14,122 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
John Buckingham Sold Out
David Einhorn Sold Out
Tweedy Browne Global Value 1,055,212 sh (-3.62%)
Daniel Loeb 51,901,767 sh (-3.62%)
Tweedy Browne 2,393,665 sh (-3.97%)
Mairs and Power 1,948,504 sh (-4.29%)
Keeley Asset Management Corp 58,610 sh (-4.70%)
Mario Gabelli 125,100 sh (-18.63%)
Richard Pzena 3,115,865 sh (-23.71%)
George Soros 284,327 sh (-36.56%)
Vanguard Health Care Fund 7,053,480 sh (-36.89%)
Joel Greenblatt 849,128 sh (-49.91%)
Paul Tudor Jones 27,459 sh (-57.55%)
Charles Brandes 75,584 sh (-75.67%)
Steven Cohen 3,600 sh (-92.94%)
» More
Q3 2016

BAX Guru Trades in Q3 2016

Steven Cohen 227,300 sh (+6213.89%)
First Eagle Investment 2,635,577 sh (+23.75%)
Paul Tudor Jones 33,174 sh (+20.81%)
John Hussman 200,000 sh (+14.29%)
Tweedy Browne Global Value 1,055,212 sh (unchged)
Tom Gayner 22,000 sh (unchged)
Daniel Loeb 51,901,767 sh (unchged)
Murray Stahl 14,122 sh (unchged)
Jeremy Grantham Sold Out
Charles Brandes Sold Out
Leucadia National Sold Out
Mario Gabelli 123,500 sh (-1.28%)
Keeley Asset Management Corp 57,410 sh (-2.05%)
Mairs and Power 1,903,688 sh (-2.30%)
Lee Ainslie 67,360 sh (-8.60%)
Tweedy Browne 2,157,391 sh (-9.87%)
George Soros 254,327 sh (-10.55%)
Joel Greenblatt 638,063 sh (-24.86%)
Vanguard Health Care Fund 4,902,940 sh (-30.49%)
Richard Pzena 1,061,577 sh (-65.93%)
Jim Simons 158,000 sh (-72.91%)
» More
Q4 2016

BAX Guru Trades in Q4 2016

Joel Greenblatt 1,271,879 sh (+99.33%)
Lee Ainslie 71,400 sh (+6.00%)
John Hussman 202,300 sh (+1.15%)
Tweedy Browne Global Value 1,055,212 sh (unchged)
Daniel Loeb 51,901,767 sh (unchged)
Tom Gayner 22,000 sh (unchged)
Steven Cohen Sold Out
Tweedy Browne 2,150,819 sh (-0.30%)
Paul Tudor Jones 32,911 sh (-0.79%)
Murray Stahl 13,922 sh (-1.42%)
Mario Gabelli 120,900 sh (-2.11%)
Mairs and Power 1,752,525 sh (-7.94%)
George Soros 184,327 sh (-27.52%)
Vanguard Health Care Fund 3,094,340 sh (-36.89%)
Jim Simons 64,100 sh (-59.43%)
Keeley Asset Management Corp 21,474 sh (-62.60%)
Richard Pzena 225,790 sh (-78.73%)
First Eagle Investment 1,100 sh (-99.96%)
» More
» Details

Insider Trades

Latest Guru Trades with BAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:OTCPK:ESLOY, NAS:ILMN, NYSE:BCR, NYSE:BDX, OTCPK:CLPBY, NAS:XRAY, NYSE:WAT, OTCPK:TRUMY, NYSE:MTD, OTCPK:OCPNY, NAS:HOLX, NYSE:RMD, NYSE:COO, OTCPK:SAUHY, NYSE:WST, NYSE:STE, NYSE:HRC, OTCPK:GNGBY, NYSE:CMD, NAS:ICUI » details
Traded in other countries:BTL.Germany, BAX.Mexico, BAX.Switzerland, 0QK8.UK,
Baxter International Inc is a healthcare company. It develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic conditions.

Baxter International Inc was incorporated in Delaware in 1931. The Company is a healthcare company. It is engaged in the development, manufacture and sale of products that save and sustain the lives of people with immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company applies a combination of medical devices, pharmaceuticals and biotechnology to create products that advance patient care. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. The Company operates in two segments namely, Hospital Products and Renal. The Hospital Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries. The Renal business also offers a portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis (PD), in-center hemodialysis (HD), home HD (HHD), continuous renal replacement therapy (CRRT) and additional dialysis services. The Company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. The Company faces substantial competition in each of its segments from international and domestic healthcare and pharmaceutical companies of all sizes. The Company's operations and many of the products manufactured or sold by the Company are subject to extensive regulation by numerous government agencies, both within and outside the United States.

Guru Investment Theses on Baxter International Inc

Bill Nygren Comments on Baxter - Jan 10, 2017

Baxter (NYSE:BAX) is a collection of disparate health care businesses, which include dialysis consumables, intravenous solutions and surgical sealants. These businesses represent what was left at Baxter following the spinoff of Baxalta in mid-2015. The businesses hadn’t been run optimally, and at the time of the spin were only producing 9% margins, which represents less than half of the levels we believe to be achievable. Baxter hired outsider Jose Almeida as CEO in late 2015. Oakmark Fund shareholders might fondly remember Almeida from his successful tenure as CEO of our long-time holding Covidien, where he fixed (and eventually sold) a collection of health care assets that had been spun out from Tyco International. We believe Almeida has the right skill set to improve Baxter’s margins and portfolio of assets, and that the company is selling at a large discount to intrinsic value.



From Bill Nygren (Trades, Portfolio)'s Oakmark Fund fourth quarter 2016 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Baxter International Inc

Bill Nygren Comments on Baxter Guru stock highlight
Baxter (NYSE:BAX) is a collection of disparate health care businesses, which include dialysis consumables, intravenous solutions and surgical sealants. These businesses represent what was left at Baxter following the spinoff of Baxalta in mid-2015. The businesses hadn’t been run optimally, and at the time of the spin were only producing 9% margins, which represents less than half of the levels we believe to be achievable. Baxter hired outsider Jose Almeida as CEO in late 2015. Oakmark Fund shareholders might fondly remember Almeida from his successful tenure as CEO of our long-time holding Covidien, where he fixed (and eventually sold) a collection of health care assets that had been spun out from Tyco International. We believe Almeida has the right skill set to improve Baxter’s margins and portfolio of assets, and that the company is selling at a large discount to intrinsic value. Read more...
Vanguard Health Care Fund Sells Amgen, Baxter The guru's largest 3rd-quarter sales
Following its third-quarter report, Vanguard Health Care Fund (Trades, Portfolio) holds 73 stocks with a total value of $46.245 billion. The following are the sales with the largest impacts on its portfolio. Read more...
Medical Companies Offer Good Value Opportunities A discussion of Peter Lynch, his top-performing strategies and good health care companies
Due to the great financial crisis, most companies were undervalued based on their valuations. Based on backtesting results, the “Peter Lynch Growth with Lower Valuation” test portfolio took positions in Baxter International Inc. (NYSE:BAX) and Abbott Laboratories (NYSE:ABT), two medical companies that reached historically low price-earnings ratios. While these companies presented good value opportunities from 2007-2011, other medical companies provide better opportunities in 2016. Read more...
2 CEOs Make Big Buys of Their Companies’ Stocks Purchases may benefit their respective companies
One of the biggest insider buys of the week occurred yesterday when Flex Pharma Inc. (NASDAQ:FLKS) president and CEO Christoph H. Westphal bought 30,334 shares at an average price of $12.42, a move that may signal a positive outlook for the company. Read more...
Baxter International Officer Invests in Stake CEO purchases 11,691 shares in the company
Jose (Joe) Almeida (Insider Trades), CEO and chairman of the board of Baxter International Inc. (BAX), acquired 11,691 shares of the company on May 23. Read more...
Dan Loeb's Third Point Portfolio Highly Concentrated The top position is in the green and tries to offset the negative performances of the other 2
Daniel Loeb´s Third Point disclosed an equity portfolio valued at some $9.86 billion at the end of the fourth quarter of 2015. The equity portfolio is mainly invested in Health Care (53%), Materials (17%) and Consumer Discretionary (11%) stocks. Read more...

Ratios

vs
industry
vs
history
PE Ratio 5.60
BAX's PE Ratio is ranked higher than
95% of the 103 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.36 vs. BAX: 5.60 )
Ranked among companies with meaningful PE Ratio only.
BAX' s PE Ratio Range Over the Past 10 Years
Min: 4.88  Med: 9.45 Max: 22.53
Current: 5.6
4.88
22.53
Forward PE Ratio 23.47
BAX's Forward PE Ratio is ranked higher than
55% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.33 vs. BAX: 23.47 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 5.61
BAX's PE Ratio without NRI is ranked higher than
94% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.92 vs. BAX: 5.61 )
Ranked among companies with meaningful PE Ratio without NRI only.
BAX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.89  Med: 10.1 Max: 115.67
Current: 5.61
4.89
115.67
Price-to-Owner-Earnings 6.12
BAX's Price-to-Owner-Earnings is ranked higher than
93% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.66 vs. BAX: 6.12 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BAX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.33  Med: 11.77 Max: 39.19
Current: 6.12
5.33
39.19
PB Ratio 3.28
BAX's PB Ratio is ranked higher than
52% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.34 vs. BAX: 3.28 )
Ranked among companies with meaningful PB Ratio only.
BAX' s PB Ratio Range Over the Past 10 Years
Min: 2.05  Med: 2.63 Max: 3.34
Current: 3.28
2.05
3.34
PS Ratio 2.74
BAX's PS Ratio is ranked lower than
51% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. BAX: 2.74 )
Ranked among companies with meaningful PS Ratio only.
BAX' s PS Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.57 Max: 2.75
Current: 2.74
1.06
2.75
Price-to-Free-Cash-Flow 29.81
BAX's Price-to-Free-Cash-Flow is ranked higher than
50% of the 70 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.79 vs. BAX: 29.81 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BAX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.96  Med: 10.1 Max: 53.93
Current: 29.81
6.96
53.93
Price-to-Operating-Cash-Flow 16.85
BAX's Price-to-Operating-Cash-Flow is ranked higher than
53% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.60 vs. BAX: 16.85 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BAX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.58  Med: 7.25 Max: 18.83
Current: 16.85
4.58
18.83
EV-to-EBIT 5.13
BAX's EV-to-EBIT is ranked higher than
94% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.50 vs. BAX: 5.13 )
Ranked among companies with meaningful EV-to-EBIT only.
BAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2940.9  Med: 8.5 Max: 63.8
Current: 5.13
-2940.9
63.8
EV-to-EBITDA 4.42
BAX's EV-to-EBITDA is ranked higher than
94% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.01 vs. BAX: 4.42 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.1  Med: 6.8 Max: 45.7
Current: 4.42
4.1
45.7
Shiller PE Ratio 11.99
BAX's Shiller PE Ratio is ranked higher than
93% of the 46 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.05 vs. BAX: 11.99 )
Ranked among companies with meaningful Shiller PE Ratio only.
BAX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.67  Med: 12.69 Max: 21.71
Current: 11.99
9.67
21.71
Current Ratio 2.40
BAX's Current Ratio is ranked higher than
56% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.27 vs. BAX: 2.40 )
Ranked among companies with meaningful Current Ratio only.
BAX' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.73 Max: 2.4
Current: 2.4
1.08
2.4
Quick Ratio 1.87
BAX's Quick Ratio is ranked higher than
64% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.59 vs. BAX: 1.87 )
Ranked among companies with meaningful Quick Ratio only.
BAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.26 Max: 1.87
Current: 1.87
0.74
1.87
Days Inventory 94.97
BAX's Days Inventory is ranked higher than
68% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. BAX: 94.97 )
Ranked among companies with meaningful Days Inventory only.
BAX' s Days Inventory Range Over the Past 10 Years
Min: 91.48  Med: 138.8 Max: 219.03
Current: 94.97
91.48
219.03
Days Sales Outstanding 70.11
BAX's Days Sales Outstanding is ranked lower than
65% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.72 vs. BAX: 70.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.53  Med: 66.28 Max: 112.88
Current: 70.11
58.53
112.88
Days Payable 47.70
BAX's Days Payable is ranked higher than
50% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 49.25 vs. BAX: 47.70 )
Ranked among companies with meaningful Days Payable only.
BAX' s Days Payable Range Over the Past 10 Years
Min: 39.5  Med: 46.3 Max: 76.67
Current: 47.7
39.5
76.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.00
BAX's Dividend Yield % is ranked lower than
65% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. BAX: 1.00 )
Ranked among companies with meaningful Dividend Yield % only.
BAX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.98  Med: 3.81 Max: 5.89
Current: 1
0.98
5.89
Dividend Payout Ratio 0.06
BAX's Dividend Payout Ratio is ranked higher than
98% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. BAX: 0.06 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BAX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.35 Max: 3.37
Current: 0.06
0.06
3.37
3-Year Dividend Growth Rate -35.90
BAX's 3-Year Dividend Growth Rate is ranked lower than
86% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.10 vs. BAX: -35.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BAX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: 0.8 Max: 22.5
Current: -35.9
-35.9
22.5
Forward Dividend Yield % 1.03
BAX's Forward Dividend Yield % is ranked lower than
68% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.39 vs. BAX: 1.03 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.47
BAX's 5-Year Yield-on-Cost % is ranked lower than
70% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.61 vs. BAX: 0.47 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BAX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.47  Med: 1.83 Max: 2.82
Current: 0.47
0.47
2.82
3-Year Average Share Buyback Ratio 0.30
BAX's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. BAX: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: -0.1 Max: 3.3
Current: 0.3
-2.1
3.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 5.94
BAX's Price-to-Tangible-Book is ranked lower than
58% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.49 vs. BAX: 5.94 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BAX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.9  Med: 5.34 Max: 10.45
Current: 5.94
3.9
10.45
Price-to-Intrinsic-Value-Projected-FCF 1.21
BAX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
82% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.99 vs. BAX: 1.21 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BAX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.05 Max: 2.34
Current: 1.21
0.53
2.34
Price-to-Median-PS-Value 1.75
BAX's Price-to-Median-PS-Value is ranked lower than
79% of the 140 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. BAX: 1.75 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BAX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.69  Med: 0.98 Max: 1.75
Current: 1.75
0.69
1.75
Price-to-Graham-Number 1.22
BAX's Price-to-Graham-Number is ranked higher than
74% of the 77 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. BAX: 1.22 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BAX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.07  Med: 1.93 Max: 5.55
Current: 1.22
1.07
5.55
Earnings Yield (Greenblatt) % 19.49
BAX's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. BAX: 19.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BAX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6  Med: 11.6 Max: 20.8
Current: 19.49
1.6
20.8
Forward Rate of Return (Yacktman) % 5.79
BAX's Forward Rate of Return (Yacktman) % is ranked lower than
66% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.07 vs. BAX: 5.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BAX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -11.8  Med: 15.5 Max: 30.5
Current: 5.79
-11.8
30.5

More Statistics

Revenue (TTM) (Mil) $10,163
EPS (TTM) $ 9.01
Beta0.70
Short Percentage of Float1.60%
52-Week Range $37.78 - 50.76
Shares Outstanding (Mil)540.08

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 10,212 10,573 10,883
EPS ($) 2.12 2.39 2.56
EPS without NRI ($) 2.12 2.39 2.56
EPS Growth Rate
(Future 3Y To 5Y Estimate)
17.86%
Dividends per Share ($) 0.61 0.61 0.67
» More Articles for BAX

Headlines

Articles On GuruFocus.com
10 Undervalued Companies for Value Investors Feb 14 2017 
Edwards Lifesciences Director Buys 3,000 Shares Feb 07 2017 
Using a Benjamin Graham Value Investing Strategy Feb 07 2017 
Daniel Loeb's Third Point Hedge Fund 4th Quarter Commentary Feb 02 2017 
10 Low P/E Stock Picks for the Defensive Investor Jan 30 2017 
4 Best Stocks for Value Investors This Week Jan 29 2017 
Steven Romick Spots Next Area of Interest, Health Care Jan 13 2017 
Bill Nygren Comments on Baxter Jan 10 2017 
10 Stocks Trading Below Their Graham Number Dec 19 2016 
10 Undervalued Stocks for the Defensive Investor Dec 15 2016 

More From Other Websites
BAXTER INTERNATIONAL INC Files SEC form 10-K, Annual Report Feb 23 2017
Baxter Declares Quarterly Dividend Feb 21 2017
Baxter Debuts Enteral Nutrition ENFit® Syringe and Accessory Line During Clinical Nutrition Week... Feb 16 2017
Baxter to Present at the 38th Annual Raymond James Institutional Investor Conference Feb 09 2017
Baxter to Present at the 37th Annual Cowen and Company Healthcare Conference Feb 08 2017
BAXTER INTERNATIONAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Other... Feb 08 2017
Baxter Appoints Dr. Stephen Oesterle to Its Board Feb 08 2017
ETFs with exposure to Baxter International, Inc. : February 6, 2017 Feb 06 2017
Baxter International, Inc. :BAX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 6, 2017 Feb 06 2017
Baxter International, Inc. :BAX-US: Earnings Analysis: 2016 By the Numbers : February 3, 2017 Feb 03 2017
Baxter International, Inc. :BAX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 3, 2017 Feb 03 2017
Baxter International (BAX) Q4 Earnings Beat, Revenues Lag Feb 01 2017
Baxter International (BAX) Q4 Earnings Beat, Sales Miss Feb 01 2017
Baxter International Inc Earnings Call scheduled for 8:30 am ET today Feb 01 2017
Baxter beats 4Q profit forecasts Feb 01 2017
Baxter beats 4Q profit forecasts Feb 01 2017
BAXTER INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 01 2017
Baxter Reports 2016 Fourth-Quarter and Full-Year Results Feb 01 2017
Q4 2016 Baxter International Inc Earnings Release - Before Market Open Feb 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)